The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives

Author(s): Zhan Gang Xiao, Jing Shen, Lin Zhang, Long Fei Li, Ming Xing Li, Wei Hu, Zhi Jie Li, Chi Hin Cho.

Journal Name: Current Medicinal Chemistry

Volume 23 , Issue 32 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Aberrant epigenetic reprogramming occurs frequently in the development of tumors. Histone H3 lysine 27 trimethylation (H3K27me3) exerts a repressive epigenetic mark on a large number of genes. UTX and JMJD3 are the only two histone demethylases which activate gene expression via demethylating H3K27me3 to H3K27me2 or H3K27me1. Current studies show that dysregulation of these two proteins are heavily linked to oncogenesis in various tissue types. Accumulating evidence suggested that there is remarkable therapeutic potential of targeting JMJD3 or UTX in different types of cancer. Herein, we shall give a brief review on the functional roles of JMJD3 and UTX in cancers and evaluate the available compounds and agents targeting UTX and JMJD3. Finally, we also discuss the several modalities that target UTX and JMJD3 for cancer therapy. This review will help to develop novel strategies to abolish or restore effects of UTX and JMJD3 in the pathogenesis of cancer.

Keywords: UTX, JMJD3, H3K27, cancer, therapeutic target.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 32
Year: 2016
Page: [3687 - 3696]
Pages: 10
DOI: 10.2174/0929867323666160725093522
Price: $58

Article Metrics

PDF: 90
HTML: 9
EPUB: 2
PRC: 2